CYCLERION THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CYCLERION THERAPEUTICS, INC. (CYCN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $51.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $51.00K, a 55.26% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $58.00K, a 49.12% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $118.00K, a 14.49% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $114.00K, a 38.04% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.04M, a 79.53% decline from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.09M, a 35.68% decline from fiscal 2021.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $7.92M, a 47.21% decline from fiscal 2020.
- CYCLERION THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $14.99M, a 4.16% decline from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $51.00K 10-Q · filed 2026-08-04 | $109.00K derived: sum of 2 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $58.00K 10-Q · filed 2026-08-04 | ||||
| 2025-12-31 | $441.00K S-4/A · filed 2026-07-22 | ||||
| 2025-09-30 | $118.00K 10-Q · filed 2025-11-12 | $232.00K derived: sum of 2 quarters · filed 2026-08-04 | $346.00K derived: sum of 3 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $114.00K 10-Q · filed 2026-08-04 | $228.00K derived: sum of 2 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $114.00K 10-Q · filed 2026-08-04 | ||||
| 2024-12-31 | $625.00K S-4/A · filed 2026-07-22 | ||||
| 2024-09-30 | $138.00K 10-Q · filed 2025-11-12 | $322.00K derived: sum of 2 quarters · filed 2025-11-12 | $503.00K derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $184.00K 10-Q · filed 2025-11-12 | $365.00K derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2024-03-31 | $181.00K 10-Q · filed 2025-11-12 | ||||
| 2023-12-31 | $1.04M 10-K/A · filed 2025-11-12 | ||||
| 2023-09-30 | $159.00K 10-Q · filed 2024-11-14 | $538.00K derived: sum of 2 quarters · filed 2024-11-14 | $964.00K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $379.00K 10-Q · filed 2024-11-14 | $373.00K 10-Q · filed 2023-07-28 | $805.00K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $426.00K 10-Q · filed 2024-11-14 | $416.00K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $5.09M 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | $1.37M 10-Q · filed 2023-11-13 | $2.78M derived: sum of 2 quarters · filed 2023-11-13 | $4.26M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $1.41M 10-Q · filed 2023-11-13 | $2.89M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $1.48M 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $7.92M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $2.02M 10-Q · filed 2022-11-03 | $3.96M derived: sum of 2 quarters · filed 2022-11-03 | $5.88M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $1.94M 10-Q · filed 2022-11-03 | $3.86M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $1.92M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $14.99M 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | $3.80M 10-Q · filed 2021-11-09 | $7.75M derived: sum of 2 quarters · filed 2021-11-09 | $11.78M derived: sum of 3 quarters · filed 2021-11-09 | $16.25M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $3.95M 10-Q · filed 2021-11-09 | $7.99M derived: sum of 2 quarters · filed 2021-11-09 | $12.46M derived: sum of 3 quarters · filed 2021-11-09 | $17.41M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-03-31 | $4.04M 10-Q · filed 2021-11-09 | $8.51M derived: sum of 2 quarters · filed 2021-11-09 | $13.45M derived: sum of 3 quarters · filed 2021-11-09 | $19.68M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2019-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $9.42M derived: sum of 2 quarters · filed 2021-02-25 | $15.64M derived: sum of 3 quarters · filed 2021-02-25 | $15.64M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $4.95M 10-Q · filed 2020-11-05 | $11.17M derived: sum of 2 quarters · filed 2020-11-05 | $11.17M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $6.22M 10-Q · filed 2020-11-05 | $6.22M 10-Q · filed 2019-08-12 | |||
| 2019-03-31 | $3.99M 10-Q · filed 2019-05-13 | ||||
| 2018-03-31 | $2.51M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |